Imugene has received approval from Western Institutional Review Board to commence Phase I clinical trial of its VAXINIA.
The US component of the Stage I trial will be done under the FDA investigational new drug (IND) process.
The clinical trial is expected to run for 2 years, and will be financed from the current budget and resources.
On 23 March 2022, Imugene shares are trading up on ASX following the announcement about the commencement of Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in multiple solid tumors in patients. It has received approval from Western Institutional Review Board (WIRB).
At AEDT 3:38 PM, IMU shares are trading at AU$0.285, up 9.615% from the previous close.
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Imugene (ASX:IMU) shares up on ASX Here’s why?
Key Takeaways:
On 23 March 2022, Imugene shares are trading up on ASX following the announcement about the commencement of Phase I clinical trial of its oncolytic virotherapy candidate, VAXINIA, in multiple solid tumors in patients. It has received approval from Western Institutional Review Board (WIRB).
At AEDT 3:38 PM, IMU shares are trading at AU$0.285, up 9.615% from the previous close.
Recent Latest News